On the morning of October 18, President Xi Jinping attended the opening ceremony of the third Belt and Road Forum for International Cooperation and delivered a keynote speech titled “Building an Open and Inclusive, Interconnected and Co-developing World”.
This year marks the 10th anniversary of President Xi’s initiative to build the Belt and Road. He pointed out that the original intention of this initiative is to draw on the ancient Silk Road, with connectivity as the main line, to strengthen policy communication, facility connectivity, trade connectivity, financial integration and people-to-people contact with other countries, to inject new impetus into the world’s economic growth, to open up a new space for global development, and to build a new platform for international economic cooperation. 10 years ago, the “Belt and Road” international cooperation went from strength to strength. In the past 10 years, “Belt and Road” international cooperation has flourished from scratch and achieved fruitful results.
Yin Weidong, chairman, president and CEO of the company, and Yang Guang, chief commercial officer, attended the opening ceremony of the “Belt and Road” International Cooperation Summit Forum as representatives, Yin Weidong told the media:
The unique contribution made by Chinese vaccines in paving the road to life and health is due to President Xi Jinping’s planning and the sharing and mutual support of many “Belt and Road” countries. The contribution made by China’s Xin Guan Vaccine is an important outcome of the “Belt and Road” and fulfills China’s commitment to make vaccines a global public good.
The unique contribution of China’s vaccines in paving the road to life and health is due to President Xi Jinping’s planning and the sharing and mutual support of many “Belt and Road” countries. The contribution made by China’s Xinguan vaccine is an important outcome of the “Belt and Road” and fulfills China’s commitment to make vaccines a global public good.
During the critical stage of Phase III clinical research of the vaccine, Kexing has efficiently promoted research cooperation with partners in Chile, Indonesia, Turkey, South Africa and other Belt and Road countries. Among them, Kexing conducted the world’s largest real-world study of the inactivated New Crown vaccine in Chile, which covered more than 10.2 million people over the age of 16, and the results of the study were eventually published in the New England Journal of Medicine. Coxin’s inactivated new crown vaccine, Kerlaflex®, is also the most widely used new crown vaccine in Chile. In the course of research and development, China’s new crown vaccine has insisted on cooperating with many “Belt and Road” countries, sharing technology and achievements, and building products and industries together. It is through the sharing and co-construction with many countries that Kexing has been able to rapidly push forward the cooperation in vaccine research and development, clinical research, and industrialization, and ultimately achieve the miracle of making the vaccine benefit more than 60 countries and regions around the world, creating nearly 3 billion doses, and becoming one of the benchmarks for the globalization of China’s vaccine industry power.
